A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Nkarta, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,155,000 shares of NKTX stock, worth $5.58 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
2,155,000
Previous 3,799,143 43.28%
Holding current value
$5.58 Million
Previous $22.5 Million 56.62%
% of portfolio
0.18%
Previous 0.47%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.52 - $8.0 $7.43 Million - $13.2 Million
-1,644,143 Reduced 43.28%
2,155,000 $9.74 Million
Q2 2024

Aug 14, 2024

SELL
$5.27 - $10.82 $7.35 Million - $15.1 Million
-1,394,944 Reduced 26.86%
3,799,143 $22.5 Million
Q1 2024

May 15, 2024

BUY
$5.59 - $15.71 $10 Million - $28.2 Million
1,794,087 Added 52.77%
5,194,087 $56.1 Million
Q4 2023

Feb 14, 2024

BUY
$1.31 - $6.6 $4.45 Million - $22.4 Million
3,400,000 New
3,400,000 $22.4 Million
Q2 2022

Aug 15, 2022

BUY
$7.77 - $19.44 $4.66 Million - $11.7 Million
600,000 New
600,000 $7.39 Million
Q1 2021

May 17, 2021

SELL
$31.33 - $59.61 $44.5 Million - $84.6 Million
-1,419,872 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$27.03 - $75.62 $27 Million - $75.5 Million
-998,900 Reduced 41.3%
1,419,872 $87.3 Million
Q3 2020

Nov 16, 2020

BUY
$23.52 - $47.9 $56.9 Million - $116 Million
2,418,772 New
2,418,772 $72.7 Million

Others Institutions Holding NKTX

About Nkarta, Inc.


  • Ticker NKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,656,800
  • Market Cap $126M
  • Description
  • Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...
More about NKTX
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.